Opinion
Video
Final Panel Thoughts on the Management of SMA
Author(s):
Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating improved gene therapy delivery systems, combination therapies, and rehabilitation models, while maintaining individualized approaches for each patient.
Clinical Brief: Future Directions in SMA Management
Main Discussion Topics
- Anticipated improvements in gene therapy delivery and safety
- Shift toward combination therapy approaches
- Evolution from palliative to rehabilitation-focused care models
- Need for ongoing basic science research to address emerging clinical questions
Key Points for Physicians
- Future gene therapies may utilize improved viral capsids with reduced liver targeting to minimize adverse events.
- Combination therapies targeting different aspects of SMA pathophysiology will likely become the standard of care.
- The care model is evolving to parallel approaches used in spinal cord injury and traumatic brain injury.
- Translational research between basic scientists and clinicians remains crucial to address emerging questions.
Notable Insights
The panel emphasized that while current treatments have transformed SMA from a frequently fatal disease to a manageable chronic condition, they are not curative and require continued research for optimization.
Clinical Significance
The future of SMA management will likely involve individualized combination approaches with safer gene delivery systems, targeted muscle-enhancing therapies, and comprehensive rehabilitation strategies to maximize functional outcomes throughout patients’ life span.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
